Eton Pharmaceuticals Soars 5.58% on Partnerships, Clinical Trials

Eton Pharmaceuticals' stock surged 5.58% in pre-market trading on April 3, 2025, driven by significant developments in the company's strategic partnerships and clinical trials.

Eton Pharmaceuticals announced the out-licensing of commercial rights to Increlex in territories outside of the U.S. to Esteve Pharmaceuticals. This move is expected to enhance the company's global presence and revenue streams, as Esteve Pharmaceuticals will handle the commercialization of Increlex in international markets.

The company is also considering a registrational Phase 3 clinical trial to evaluate sirexatamab plus bevacizumab and chemotherapy in second-line MSS CRC patients. This trial could potentially expand the therapeutic options for patients with metastatic colorectal cancer, further solidifying Eton Pharmaceuticals' position in the oncology market.